SGLT-2 Therapy Center

Why and when to use this therapy to treat patients who have type 2 diabetes.

Subanalysis of CANVAS program shows slower progression of kidney disease, reduction in weight, reduction in A1c and even drop in blood pressure.

Most important mediator due to changes in markers of plasma volume.

Canagliflozin is found to have reduced risk of cardiovascular death or hospitalization due to heart failure in type 2 diabetes patients.

In part 2 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the actual cost to the lives of patients who are put on more expensive, but life-saving, diabetes drugs.

Post-hoc analysis of the breakthrough EMPA-REG Outcome trial demonstrated reduction in composite cardiovascular outcomes that can be seen with empagliflozin therapy.

It is unclear whether SGLT2i show reduction in mortality in all patients with type 2 or just in patients with type 2 diabetes with increased cardiovascular risk.

Researchers complete examination of class of type 2 medication.

Therapy offers beneficial weight loss in treatment of diabetes, but which agent in the class leads to the greatest body weight reduction?

Dr. Jim McDermott is Vice President of US Medical Affairs for Diabetes at AstraZeneca. He has been with AstraZeneca for more than two decades.